The RevoLix 2 Micron Continuous Wave Laser Vaporesection for the Treatment of High-Risk Patients with Benign Prostatic Hyperplasia

Abstract

The RevoLix 70W 2-μm continuous wave laser vaporesection is safe and effective in the treatment of high-risk patients with BPH.

Long-term outcome following thulium vaporesection of the prostate

“…Since then, multiple sources have sited various data regarding the safety and efficiency of this procedure in regards to different prostate sizes and various conditions. In the published paper as presented by, Si et al ThuVaRP is safe and effective in the treatment of BPH in high‐risk patients with an average age of 82.6 years old. The data presented by the Macchione et al paper confirmed the safety of ThuVaRP in patients on continuous oral anticoagulant or anti‐platelet therapy; with less blood loss and promising outcomes in a 6‐month follow‐up.…”

Thulium laser vaporesection versus standard transurethral resection of the prostate: A randomized trial with transpulmonary thermodilution hemodynamic monitoring

“…12 Recent prospective studies comparing TmLRP and TURP confirmed that with similar improvements in voiding parameters, the TmLRP was superior in intraoperative safety and perioperative results, including catheter drainage time and hospital stay. 12,19,20 However, to date, there are few reports on the preand postoperative changes in hemodynamics in patients with BPH, especially with TmLRP and TURP.…”

The RevoLix™ 2 μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up

“…We have previously reported the safety and efficiency of the 2 lm CW laser vaporesection of the prostate in a recent article. 6 Long-term outcomes using the RevoLix thulium laser system for the treatment of BPH are lacking. In our study, the outcomes showed significant and sustained improvements at each clinic follow-up visit.…”